Diabetic Macular Edema

Study reveals faricimab effectively treats diabetic macular edema in underrepresented minorities, showing significant visual acuity improvements and safety across diverse patient populations.

Ophthalmologist Dilraj Grewal explores cutting-edge clinical trials for uveitis treatment, highlighting new targeted therapies that aim to control inflammation and macular edema with fewer steroid-related side effects.

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and diabetic macular edema (DME).

Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib for the treatment of AMD and DME.

Four-year study shows faricimab in treat-and-extend regimen maintains vision for diabetic macular edema patients with significantly fewer injections over time.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

The recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein will be intravitreally administered in up to 150 patients.

According to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema.

In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab.

KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation.

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.

Brazilian researchers used swept-source OCT and OCT-angiography to study the effects of an initial dose of aflibercept on untreated diabetic macular edema in patients.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact.

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

Hashad is a retinal specialist with over 25 years of leadership experience in global research and development.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported

Visual acuity with both approaches was comparable and the device was efficacious and safe.

This database could enhance the workflow of eye care professionals with its in-depth reference data for retinal layer thickness and optic nerve head metrics.

Apellis Pharmaceuticals and EyePoint Pharmaceuticals are both scheduled to present at the conference.

A look at the current state of AI in diabetic eye disease and where the future may take us.

Ramiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.